课题基金 / 基金详情

项目摘要

项目成果

Cory Berkland的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):我们的长期目标是广泛使用PPF技术,以促进有效生产具有统一大小和物理特征的药物包囊微粒,这种微粒可以在单次给药后在体内多天时间内以受控的速度释放特定药物。对于这项建议,我们特别针对的是具有精确定制的药物释放特征的慢性疼痛的成本和剂量效益管理。慢性疼痛在美国困扰着大量人口。更安全(计划外)阿片类药物的缓释制剂可以提高患者的依从性和药物疗效,并可以限制突破性疼痛的可能性,所有这些都不会使患者面临成瘾的风险。然而,现有的阿片缓释制剂是不够的,而且仅限于提供最多24小时的缓解。该项目旨在使用曲马多,一种非预定的阿片类药物,旨在创造一种可注射形式的长效(最长5天)曲马多制剂,以增强止痛作用,并填补制药市场的关键创新空白。本应用的具体目标是模拟恒定输液泵状给药(特定目标1),优化采用PPF技术生产的具有5天零级药物释放曲线的曲马多微球,并验证曲马多体内缓释制剂(特定目标2)所取得的结果。我们的总体假设是,使用PPF技术生产的均匀微球开发的延长疼痛控制疗法将以精确定制的药物释放特性提供成本和剂量效益的慢性疼痛治疗,与使用传统方法制造的曲马多负载微球相比,它将提供更可控制和可预测的药物释放,与当代商业上可获得的缓释疼痛治疗产品(例如ULTRAM(R))相比,显著改善受控释放特性。多天慢性疼痛管理疗法具有为疼痛管理提供革命性替代方案的潜力。 公共卫生相关性:慢性疼痛在美国困扰着大量人口。更安全(计划外)阿片类药物的缓释制剂可以提高患者的依从性和药物疗效,并可以限制突破性疼痛的可能性,所有这些都不会使患者面临成瘾的风险。然而,现有的阿片缓释制剂是不够的,而且仅限于提供最多24小时的缓解。该项目旨在使用曲马多,一种非预定的阿片类药物,旨在创造一种可注射形式的长效(最长5天)曲马多制剂,以增强止痛作用,并填补制药市场的关键创新空白。
英文摘要
DESCRIPTION (provided by applicant): Our long term goal is to widespread the use of PPF technology for promoting effective production of drug-encapsulating microparticles with uniform size and physical characteristics that can be leveraged to release a specific drug at controlled rates over multi-day periods in vivo after a single administration. For this proposal, we are specifically targeting a cost and dose-effective management of chronic pain with precisely tailored drug release characteristics. Chronic pain afflicts a large population in United States. Extended release formulations of safer (unscheduled) opioids can improve patient compliance and drug efficacy, and can limit the possibility of breakthrough pain, all without putting the patients at the risk of addiction. However, existing extended release opioid formulations are insufficient, and are limited to providing relief up to a maximum of 24 h. Using tramadol, an unscheduled opioid, this project aims to create a long-acting (up to 5-day) tramadol formulation in an injectable form to enhance pain relief and fill a critical innovation gap in the pharmaceutical market. The specific objective of this application is to optimize tramadol-loaded microspheres produced by PPF technology with a 5 day zero-order drug release profiles, imitating a constant infusion pump-like dosing (Specific Aim 1), and validate the results achieved with extended release formulations of tramadol in vivo (Specific Aim 2). Our overall hypothesis is that extended pain management therapy developed using uniform microspheres produced by PPF technology will offer a cost and dose-effective management of chronic pain with precisely tailored drug release characteristics, which will provide a more controlled and predictable drug release compared to tramadol-loaded microspheres fabricated using conventional methods, and significantly improve controlled release characteristics compared to contemporary commercially-available sustained-release pain management products (e.g., ULTRAM(R)). Multi-day chronic pain management therapy holds the potential to provide a revolutionary alternative for pain management. PUBLIC HEALTH RELEVANCE: Chronic pain afflicts a large population in United States. Extended release formulations of safer (unscheduled) opioids can improve patient compliance and drug efficacy, and can limit the possibility of breakthrough pain, all without putting the patients at the risk of addiction. However, existing extended release opioid formulations are insufficient, and are limited to providing relief up to a maximum of 24 h. Using tramadol, an unscheduled opioid, this project aims to create a long- acting (up to 5-day) tramadol formulation in an injectable form to enhance pain relief and fill a critical innovation gap in the pharmaceutical market.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preparing BBI-001 as an oral, non-absorbed iron chelator for prevention of iron overload
  • 批准号:
    10258539
  • 项目类别:
  • 资助金额:
    $29.94万
  • 财政年份:
    2021
  • 负责人:
    Cory Berkland
  • 依托单位:
Engineering Microparticles for Taste-Masking and Controlled Release of Pediatric
  • 批准号:
    8396082
  • 项目类别:
  • 资助金额:
    $21.6万
  • 财政年份:
    2012
  • 负责人:
    Cory Berkland
  • 依托单位:
Precision Particle Fabrication-enabled Betamethasone-loaded Microspheres for Tran
  • 批准号:
    8396087
  • 项目类别:
  • 资助金额:
    $28.71万
  • 财政年份:
    2012
  • 负责人:
    Cory Berkland
  • 依托单位:
Integrative colloidal gels for cranial defect repair
  • 批准号:
    8433328
  • 项目类别:
  • 资助金额:
    $35.71万
  • 财政年份:
    2012
  • 负责人:
    Cory Berkland
  • 依托单位:
海外基金